Literature DB >> 34295081

Nerve-Sparing Postchemotherapy Retroperitoneal Lymph Node Dissection (PC RPLND) for Nonseminomatous Germ Cell Tumour: Experience from a Tertiary Cancer Centre.

Anand Raja1, Kanuj Malik1, N Kathiresan2, Venkatraman Radhakrishnan3.   

Abstract

Postchemotherapy RPLND remains an integral part of management of testicular tumours. Nerve-sparing techniques can minimize the ejaculatory dysfunction due to the procedure. We report our functional and oncological outcomes for nerve-sparing RPLND in postchemotherapy settings. We analysed data from all patients undergoing nerve-sparing PC RPLND from January 1990 to December 2013 at our institute. Antegrade ejaculation and fertility issues were determined by patient history. Nerve sparing was achieved in 30% of patients undergoing PC RPLND. Of the 33 patients who underwent nerve-sparing PC RPLND, 19 (57.8%) had antegrade ejaculation. The mean time to antegrade ejaculation was 6.8 months. After a median follow-up of 75.61 months, 5-year disease-free survival was 98%. Nerve-sparing RPLND can improve functional outcomes without increasing recurrence rates in post chemotherapy setting. © Indian Association of Surgical Oncology 2021.

Entities:  

Keywords:  Ejaculation; Fertility; Follow-up studies; Lymph node excision; Testicular neoplasm

Year:  2021        PMID: 34295081      PMCID: PMC8272781          DOI: 10.1007/s13193-021-01313-9

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  21 in total

1.  Nerve sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma.

Authors:  G R Wahle; R S Foster; R Bihrle; R G Rowland; R M Bennett; J P Donohue
Journal:  J Urol       Date:  1994-08       Impact factor: 7.450

2.  Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Timothy Gilligan; Daniel W Lin; Rahul Aggarwal; David Chism; Nicholas Cost; Ithaar H Derweesh; Hamid Emamekhoo; Darren R Feldman; Daniel M Geynisman; Steven L Hancock; Chad LaGrange; Ellis G Levine; Thomas Longo; Will Lowrance; Bradley McGregor; Paul Monk; Joel Picus; Phillip Pierorazio; Soroush Rais-Bahrami; Philip Saylor; Kanishka Sircar; David C Smith; Katherine Tzou; Daniel Vaena; David Vaughn; Kosj Yamoah; Jonathan Yamzon; Alyse Johnson-Chilla; Jennifer Keller; Lenora A Pluchino
Journal:  J Natl Compr Canc Netw       Date:  2019-12       Impact factor: 11.908

3.  Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer.

Authors:  C L Coogan; M J Hejase; G R Wahle; R S Foster; R G Rowland; R Bihrle; J P Donohue
Journal:  J Urol       Date:  1996-11       Impact factor: 7.450

4.  Fertility in patients treated for testicular cancer.

Authors:  Erika Matos; Breda Skrbinc; Branko Zakotnik
Journal:  J Cancer Surviv       Date:  2010-07-03       Impact factor: 4.442

5.  Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor.

Authors:  Murilo A Luz; Ahmed F Kotb; Saad Aldousari; Fadi Brimo; Simon Tanguay; Wassim Kassouf; Armen G Aprikian
Journal:  World J Surg Oncol       Date:  2010-11-09       Impact factor: 2.754

6.  Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer.

Authors:  Hannes Steiner; Florian Zangerl; Brigitte Stöhr; Thomas Granig; Henry Ho; Georg Bartsch; Reinhard Peschel
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

7.  Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors.

Authors:  Prabhjot Singh; Siddharth Yadav; Sanjay Mahapatra; Amlesh Seth
Journal:  Indian J Urol       Date:  2016 Jan-Mar

8.  Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.

Authors:  Axel Heidenreich; David Pfister; Ralf Witthuhn; David Thüer; Peter Albers
Journal:  Eur Urol       Date:  2008-09-24       Impact factor: 20.096

9.  Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.

Authors:  Brett S Carver; Bobby Shayegan; Scott Eggener; Jason Stasi; Robert J Motzer; George J Bosl; Joel Sheinfeld
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.